Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pre-exposure Prophylaxis (PrEP) for People Who Inject Drugs (PWID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03869671
Recruitment Status : Not yet recruiting
First Posted : March 11, 2019
Last Update Posted : March 2, 2021
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Boston University

Brief Summary:

People who inject drugs (PWID) experience high risk of HIV acquisition. Antiretroviral pre-exposure prophylaxis (PrEP) is an efficacious biomedical HIV prevention strategy for high risk HIV-uninfected individuals including PWID, yet uptake has been low in this population and uptake and adherence interventions have not been developed or tested. Drawing from formative qualitative research, the overall goal of this project is to develop an intervention to promote PrEP uptake and adherence among PWID in the U.S. Northeast. The investigators will:

  • Analyze existing literature and data to identify specific barriers and facilitators to PrEP uptake and adherence among PWID to inform the initial adaptation of existing theory-based interventions;
  • Conduct qualitative interviews with ~30 PWID and ~10 key informants (PrEP and other clinical and social service providers) to identify intervention targets;
  • Develop and iteratively refine and finalize an intervention manual based on feedback from qualitative exit-interviews with an interventionist and ~10 PWID; and
  • Conduct a pilot randomized clinical trial (RCT) in ~50 HIV-uninfected PWID to compare PrEP uptake and adherence outcomes and assess intervention feasibility and acceptability.

Condition or disease Intervention/treatment Phase
Intravenous Drug Abuse Behavioral: PrEP uptake/adherence intervention Behavioral: Harm reduction standard of care Not Applicable

Detailed Description:

This mixed methods phased research will use qualitative and quantitative techniques to improve PrEP uptake and adherence among PWID through the following three phases:

  • Phase 1 will identify the modifiable determinants of PrEP uptake and adherence among HIV-uninfected PWID using in-depth qualitative interviews with PWID and key informants (KIs). Qualitative interviews will explore perceived acceptability and identify barriers and facilitators to PrEP uptake and adherence among ~30 HIV-uninfected PWID and explore perspectives on optimal PrEP delivery methods with ~15 KIs (e.g., PrEP physicians, community-based organization staff members with experience working with PWID).
  • Phase 2 will involve identifying intervention targets and adapting existing intervention strategies to improve PrEP uptake and adherence among PWID. This will involve reviewing the literature to identify and select components of existing, evidence-based medication adherence interventions to adapt for the unique determinants of PrEP uptake and adherence among PWID. Investigators will then develop and iteratively refine and finalize an intervention manual by conducting an open-pilot of the intervention in a community-based setting. Refinements will be based on feedback from qualitative exit-interviews with the interventionist and ~10 PWID.
  • Phase 3 will involve pilot testing the resulting PrEP uptake and adherence intervention in a selected community-based setting to obtain preliminary data on PrEP uptake and adherence outcomes (primary outcomes) and intervention feasibility and acceptability (secondary outcomes). Investigators will use a pilot RCT design with a mixed methods process evaluation in which 50 HIV-uninfected PWID will be randomized to the PrEP intervention or a control condition (SEP standard of care; n=25 per arm). Investigators will assess changes in PrEP outcomes (primary outcomes of uptake and adherence) and key implementation measures (e.g., secondary outcomes of acceptability, feasibility, adoption by the interventionist).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Optimizing Bio-behavioral HIV Prevention Approaches for People Who Inject Drugs
Estimated Study Start Date : March 2021
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: PrEP uptake/adherence intervention
A trained interventionist will deliver the manualized, single session PrEP uptake/adherence intervention in private counseling rooms at a community-based setting.
Behavioral: PrEP uptake/adherence intervention
The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses). The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.

Active Comparator: Harm reduction standard of care
Participants will be provided harm reduction supplies and health information and counseling according to routine practice at the community-based setting.
Behavioral: Harm reduction standard of care
Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).




Primary Outcome Measures :
  1. PrEP uptake by self-report [ Time Frame: 1 month ]
    measured using 1 item in a structured questionnaire

  2. PrEP uptake by self-report [ Time Frame: 3 months ]
    measured using 1 item in a structured questionnaire

  3. PrEP uptake by pharmacy records [ Time Frame: 1 month ]
    measured by accessing pharmacy records

  4. PrEP uptake by pharmacy records [ Time Frame: 3 months ]
    measured by accessing pharmacy records

  5. PrEP adherence by self-report [ Time Frame: 1 month ]
    measured using 1 item in a structured questionnaire to determine the proportion of doses taken as prescribed

  6. PrEP adherence by self-report [ Time Frame: 3 months ]
    measured using 1 item in a structured questionnaire to determine the proportion of doses taken as prescribed

  7. PrEP adherence by dried blood spot [ Time Frame: 1 month ]
    measured via detection of tenofovir and emtricitabine in dried blood spots (DBS)

  8. PrEP adherence by dried blood spot [ Time Frame: 3 months ]
    measured via detection of tenofovir and emtricitabine in dried blood spots (DBS)


Secondary Outcome Measures :
  1. Participant satisfaction with intervention content [ Time Frame: 1 month ]
    assessed via qualitative exit interviews exploring satisfaction with the intervention content (including an open-ended question on topics that were helpful and unhelpful)

  2. Participant satisfaction with intervention delivery methods [ Time Frame: 1 month ]
    assessed via qualitative exit interviews exploring satisfaction with the intervention delivery methods (including an open-ended question on how helpful or unhelpful the intervention delivery methods were)

  3. Interventionist satisfaction with training materials [ Time Frame: 1 month ]
    assessed via qualitative exit interviews exploring satisfaction with the training materials for interventionists (including an open-ended question on how helpful or unhelpful the training materials were)

  4. Interventionist satisfaction with intervention manual [ Time Frame: 1 month ]
    assessed via qualitative exit interviews exploring satisfaction with the intervention manual (including an open-ended question on how helpful or unhelpful the intervention manual was)

  5. Interventionist satisfaction with intervention content [ Time Frame: 1 month ]
    assessed via qualitative exit interviews exploring satisfaction with the intervention content (including an open-ended question on topics that were helpful and unhelpful)

  6. Interventionist satisfaction with intervention delivery methods [ Time Frame: 1 month ]
    assessed via qualitative exit interviews exploring satisfaction with the training materials, intervention manual, intervention content, intervention delivery methods (including an open-ended question on how helpful or unhelpful the intervention delivery methods were)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For all phases:

Inclusion Criteria:

  • An adult PWID
  • Self report of any high risk behaviors for HIV (past-month receptive syringe sharing, transactional sex, condomless sex with an HIV-infected or unknown status partner)

Exclusion Criteria:

  • Unable or unwilling to provide informed consent

For Phase 3 (the RCT pilot):

Inclusion Criteria:

  • Clinically eligible for PrEP (confirmed HIV-uninfected status, adequate renal function [estimated creatinine clearance ≥60 ml/min], and documented hepatitis B virus [HBV] status)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03869671


Contacts
Layout table for location contacts
Contact: Angela Bazzi, PhD, MPH 617-358-1361 abazzi@bu.edu
Contact: Joel Earlywine, BA 617-358-1609 earlyjj@bu.edu

Sponsors and Collaborators
Boston University
National Institute on Drug Abuse (NIDA)
Investigators
Layout table for investigator information
Principal Investigator: Angela Bazzi, PhD, MPH Boston University
Layout table for additonal information
Responsible Party: Boston University
ClinicalTrials.gov Identifier: NCT03869671    
Other Study ID Numbers: H-34960
K01DA043412-01A1 ( U.S. NIH Grant/Contract )
First Posted: March 11, 2019    Key Record Dates
Last Update Posted: March 2, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Boston University:
Antiretroviral pre-exposure prophylaxis (PrEP)
Syringe exchange program (SEP)
HIV-related risk behaviors
Adherence intervention
People who inject drugs (PWID)
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Substance Abuse, Intravenous
Chemically-Induced Disorders
Mental Disorders